BMI View: Leveraging Vietnam's National Expanded Immunisation Programme (EPI) will be of strategic
benefit to multinational pharmaceutical firms with a strong vaccines portfolio. Government support for the
initiative is expected to remain strong, which bodes well for ..."
BMI View: Vietnam's disease profile will be increasingly attractive for prescription drugmakers as chronic
conditions become more prevalent. To adequately meet this large unmet medical need, pharmaceutical
firms will have to adapt their product portfolios to account f ..."
BMI View: Vietnam will be a highly attractive market for private healthcare providers in the region.
Beyond the expected strong increases in healthcare spending, there are also significant service gaps in the
market that will provide revenue earning opportunities to c ..."
BMI View: The use of telecare in Vietnam's healthcare sector will grow. This will be facilitated by the
increasing use of internet services in the country as well the government's focus on leveraging telecare
services to improve healthcare access in the Vietnam areas ..."
BMI View: Counterfeit and substandard medicines will remain highly pervasive in Vietnam's
pharmaceutical market. While this reflects the limited capacity of regulators to address the problem, its
persistence also illustrates the presence of a sizeable market for manuf ..."
BMI View: With a growing and ageing population, Vietnam plays host to an attractive target for
pharmaceutical and healthcare growth. While per capita spending remains low, and current healthcare
infrastructure appears strained, access to healthcare coverage is steadil ..."
BMI View: The attractiveness of Vietnam's pharmaceutical market is steadily increasing. While structural
challenges remain, such as the country's increasingly ageing population and under-capacity in terms of
healthcare infrastructure and personnel, growth in expenditu ..."
BMI View: Extensive bureaucracy and a lack of human resources in regulatory agencies are the two key
reasons for the market barriers that innovative pharmaceutical firms face in accessing Vietnam's
pharmaceutical market. Despite these obstacles, we maintain that overr ..."
BMI View: Vietnam's reliance on imported drugs (both generic and patented) will continue to
provide ample commercial opportunities for foreign drugmakers. However, the population's concerns over
drug quality means that only companies with relatively positive branding ..."
BMI View: The upgrade to our private healthcare forecast stems largely from the Vietnamese government's
plan to pass hospital operating costs to patients. We highlight that this is potentially regressive should
hospitals attempt to profit from such policies. Neverthel ..."